SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization.
Quality Score
4/10
Citations
0
Subjects
Non-Human
Study Design
Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.
Our Assessment
Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.
Findings in Context
The results for SS-31 are encouraging.
On the Limitations
Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.
The Takeaway
Bottom line: Early-stage evidence for SS-31. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.
Key Findings
The study found that SS-31 significantly improved survival rates and reduced neurological deficits in a rat model of cardiac arrest, likely through inhibiting microglial ferroptosis and promoting an anti-inflammatory shift in polarization via the regulation of Sesn2 signaling pathway.
Limitations
This is a preclinical animal study with limitations inherent to such models, including potential differences between rodent physiology and human responses. Additionally, the study's findings may not be directly translatable to clinical settings without further research.
Citation
Jiang Tangxing, Zhang Huidan, Sun Yijun et al.. (2026). SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. https://doi.org/10.1016/j.neurot.2025.e00772
Related Papers
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.
Song Zengtao et al. · Neurochemistry international · 2026
New insight for SS‑31 in treating diabetic cardiomyopathy: Activation of mitoGPX4 and alleviation of mitochondria‑dependent ferroptosis.
Xiong Lie et al. · International journal of molecular medicine · 2024
Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage.
Xia Yuanyou et al. · Journal of nanobiotechnology · 2024
This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.